SCYNEXIS is a biotechnology company based in Jersey City, New Jersey, that develops products for fungal infections, including vulvovaginal candidiasis. Its main product candidate is Ibrexafungerp, an oral and intravenous drug intended for the treatment of various fungal infections, from recurrent VVC to invasive aspergillosis. The company has research collaborations with multiple organizations, including Merck and R-Pharm.